Thombocyte function in relation to the long term application of medroxyprogesterone acetate as a female contraceptive agent
Mettler, L.; Shirwani, D.; Brunnberg, F.J.
Journal of Postgraduate Medicine 25(3): 154-157
1979
ISSN/ISBN: 0022-3859 PMID: 529167 Document Number: 447848
Document emailed within 1 workday
Related Documents
Soichet, S. 1969: Depo-provera (medroxyprogesterone acetate) as a female contraceptive agent International Journal of Fertility 14(1): 33-38Wakatsuki, A.; Okatani, Y.; Fukaya, T. 2003: Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance Circulation 107(20): E197; Author Reply E197
Jeppsson, S.; Gershagen, S.; Johansson, E. D. B.; Rannevik, G. 1982: Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera(R)) as a contraceptive agent European Journal of Endocrinology 99(3): 339-343
Modesto, W.; Bahamondes, M.V.; Bahamondes, L. 2015: Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate Journal of Women's Health 24(8): 636-640
Powell, L.C.; Seymour, R.J. 1971: Effects of depo-medroxyprogesterone acetate as a contraceptive agent American Journal of Obstetrics and Gynecology 110(1): 36-41
Linthorst, G.; Wibaut, E.P.; de Jongh, R.E. 1972: Experiences with a 3-monthly injections of medroxyprogesterone acetate (MPA) as a contraceptive agent Nederlands Tijdschrift Voor Geneeskunde 116(38): 1694-1698
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Jeppsson, S. 1972: Experience with depo-medroxyprogesterone acetate (Depo-Provera) as a contraceptive agent Acta Obstetricia et Gynecologica Scandinavica 51(3): 257-263
Jeppsson, S. 1972: Experience with depo-medroxyprogesterone acetate (Depo-Provera) as a contraceptive agent Acta Obstetricia et Gynecologica Scandinavica 51(3): 257-263
Jeppsson, S. 1972: Experience with depo-medroxyprogesterone acetate (Depo-Provera) as a contraceptive agent Acta Obstetricia et Gynecologica Scandinavica 51(3): 257-263
Lizarelli, P.íc.M.; Martins, W.P.; Vieira, C.S.; Soares, G.M.; Franceschini, S.íl.A.ôn.; Ferriani, R.A.; Patta, M.C. 2009: Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women Contraception 79(1): 35-40
Cundy, T.; Cornish, J.; Roberts, H.; Reid, I.R. 2002: Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception American Journal of Obstetrics and Gynecology 186(5): 978-983
Cheewadhanaraks, S. 2013: Cumulative recurrence rates of endometriosis-associated pain after long-term intramuscular depot medroxyprogesterone acetate therapy Journal of the Medical Association of Thailand 96(2): 140-143
Tomasicchio, M.; Avenant, C.; Du Toit, A.; Ray, R.M.; Hapgood, J.P. 2013: The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor PLOS one 8(5): E62895
Govender, Y.; Avenant, C.; Verhoog, N.J.D.; Ray, R.M.; Grantham, N.J.; Africander, D.; Hapgood, J.P. 2014: The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor Plos one 9(5): E96497
Africander, D.; Louw, R.; Verhoog, N.; Noeth, D.; Hapgood, J.P. 2011: Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract Contraception 84(4): 423-435
el-Mahgoub, S.; Karim, M.; Ammar, R. 1972: Long-term use of depot medroxy progesterone acetate as a contraceptive Acta Obstetricia et Gynecologica Scandinavica 51(3): 251-255
Wong, A.Y.K.; Tang, L.C.H.; Chin, R.K.H. 2010: Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial Australian and New Zealand Journal of Obstetrics and Gynaecology 50(3): 273-279
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Peng, Q. 1985: Sister-chromatid exchange studies in women with long-term use of the oral contraceptive pills megestrol acetate compositas Zhonghua Fu Chan Ke Za Zhi 20(5): 309